NOVO NORDISK A S
NONOFDrugs in Pipeline
47
Phase 3 Programs
39
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
biphasic human insulin
Diabetes
Cagrilintide
Obesity
insulin aspart
Diabetes
liraglutide
Diabetes
insulin degludec/liraglutide
Diabetes
Mim8
Haemophilia A With or Without Inhibitors
rosiglitazone
Diabetes
insulin degludec/insulin aspart
Diabetes
Ziltivekimab
Cardiovascular Risk
biphasic insulin aspart
Diabetes
exenatide
Diabetes
Tirzepatide
Obesity
IcoSema
Diabetes Mellitus, Type 2
Concizumab
Haemophilia A With Inhibitors
Norditropin®
SGA, Turner Syndrome, Noonan Syndrome, ISS
biphasic insulin aspart 50
Diabetes
semaglutide 2.4 mg
Obesity
activated recombinant human factor VII
Acquired Bleeding Disorder
Insulin Icodec
Diabetes Mellitus, Type 2
insulin degludec
Diabetes
Semaglutide
Diabetes Mellitus, Type 2
catridecacog
Congenital Bleeding Disorder
Turoctocog alfa pegol
Congenital Bleeding Disorder
Somapacitan
Growth Hormone Deficiency in Children
insulin detemir
Diabetes
metformin
Diabetes
insulin glargine
Diabetes
sitagliptin
Diabetes
biphasic insulin aspart 30
Diabetes
NPH insulin
Diabetes Mellitus, Type 1
Faster-acting insulin aspart
Diabetes
insulin NPH
Diabetes
Nonacog beta pegol
Haemophilia B
glimepiride
Diabetes
biphasic insulin aspart 70
Diabetes
turoctocog alfa
Congenital Bleeding Disorder
Oral semaglutide
Obesity
somatropin
Growth Hormone Disorder
Dulaglutide
Diabetes
NNC126-0083
Growth Hormone Disorder
NNC6019-0001
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Etavopivat
Sickle Cell Disease
NNC0519-0130
Obesity
CagriSema (Cagrilintide B and Semaglutide I)
Diabetes Mellitus, Type 2
DCR-PHXC
Primary Hyperoxaluria Type 1
NNC0114-0006
Inflammation
eptacog alfa (activated)
Acquired Bleeding Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
biphasic human insulin | Phase 3 | Diabetes | - | - |
Cagrilintide | Phase 3 | Obesity | - | - |
insulin aspart | Phase 3 | Diabetes | - | - |
liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec/liraglutide | Phase 3 | Diabetes | - | - |
Mim8 | Phase 3 | Haemophilia A With or Without Inhibitors | - | - |
rosiglitazone | Phase 3 | Diabetes | - | - |
insulin degludec/insulin aspart | Phase 3 | Diabetes | - | - |
Ziltivekimab | Phase 3 | Cardiovascular Risk | - | - |
biphasic insulin aspart | Phase 3 | Diabetes | - | - |
exenatide | Phase 3 | Diabetes | - | - |
Tirzepatide | Phase 3 | Obesity | - | - |
IcoSema | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Concizumab | Phase 3 | Haemophilia A With Inhibitors | - | - |
Norditropin® | Phase 3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | - | - |
biphasic insulin aspart 50 | Phase 3 | Diabetes | - | - |
semaglutide 2.4 mg | Phase 3 | Obesity | - | - |
activated recombinant human factor VII | Phase 3 | Acquired Bleeding Disorder | - | - |
Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
insulin degludec | Phase 3 | Diabetes | - | - |
Semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
catridecacog | Phase 3 | Congenital Bleeding Disorder | - | - |
Turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
Somapacitan | Phase 3 | Growth Hormone Deficiency in Children | - | - |
insulin detemir | Phase 3 | Diabetes | - | - |
metformin | Phase 3 | Diabetes | - | - |
insulin glargine | Phase 3 | Diabetes | - | - |
sitagliptin | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 30 | Phase 3 | Diabetes | - | - |
NPH insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Faster-acting insulin aspart | Phase 3 | Diabetes | - | - |
insulin NPH | Phase 3 | Diabetes | - | - |
Nonacog beta pegol | Phase 3 | Haemophilia B | - | - |
glimepiride | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 70 | Phase 3 | Diabetes | - | - |
turoctocog alfa | Phase 3 | Congenital Bleeding Disorder | - | - |
Oral semaglutide | Phase 3 | Obesity | - | - |
somatropin | Phase 3 | Growth Hormone Disorder | - | - |
Dulaglutide | Phase 3 | Diabetes | - | - |
NNC126-0083 | Phase 2 | Growth Hormone Disorder | - | - |
NNC6019-0001 | Phase 2 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | - | - |
Etavopivat | Phase 2 | Sickle Cell Disease | - | - |
NNC0519-0130 | Phase 2 | Obesity | - | - |
CagriSema (Cagrilintide B and Semaglutide I) | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
DCR-PHXC | Phase 2 | Primary Hyperoxaluria Type 1 | - | - |
NNC0114-0006 | Phase 2 | Inflammation | - | - |
eptacog alfa (activated) | Phase 2 | Acquired Bleeding Disorder | - | - |